Case Reports
Early Access
https://doi.org/10.4081/dr.2025.10614

The role of calcium serum level in clinical manifestation and progress of psoriasis vulgaris in a patient with Fahr’s syndrome

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 28 October 2025
153
Views
82
Downloads
Psoriasis vulgaris, Fahr’s syndrome, hypocalciemia, hypoparathyroidism, basal ganglia calcification, psychiatry

Authors

Migena Vargu
mvargu@yahoo.com
Department of Dermatology, University Hospital Center “Mother Teresa”, University of Medicine, Tirana, Albania.
Sabina Dedej
Faculty of Medicine, University of Medicine, Tirana, Albania.
Petrit Vargu
Faculty of Medicine, University of Medicine, Tirana, Albania.
Eriselda Kurushi
Department of Pathology, University Hospital Center “Mother Teresa”, Tirana, Albania.
Anxhela Nisi
Department of Dermatology, University Hospital Center “Mother Teresa”, University of Medicine, Tirana, Albania.
Samuele Vargu
Faculty of Medicine, University of Medicine, Tirana, Albania.

Fahr’s syndrome is a rare entity characterized by symmetrical and bilateral non-atherosclerotic intracerebral calcifications in the basal ganglia. This entity is usually asymptomatic or may present mainly with neuro-neuropsychiatric and dermatological manifestations. Secondary bilateral striopallidodentate calcinosis (BSPDC) presentations are associated with various diseases. We describe a case of psoriasis vulgaris associated with secondary BSPDC due to hypoparathyroidism. Laboratory tests revealed hypocalcemia, hyperphosphatemia, and a low parathormone serum level; in cerebral computed tomography (CT), bilateral basal ganglia calcification was observed. Correction of calcium deficiency restored the calcium-phosphate balance and led to an improvement in psoriatic lesions. Psoriasis vulgaris is a common condition that may be associated with disturbances in calcium metabolism. Dermatologists should be aware that investigating cases resistant to conventional therapies can uncover underlying systemic disorders that significantly affect patients’ quality of life.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Pereira GS, Ferreira A, Castro L, et al. From cranial nerve palsy to seizures—All the signs that lead to secondary Fahr’s syndrome. Clin Case Rep 2021;9:e03669. DOI: https://doi.org/10.1002/ccr3.3669
2. Marinković DM, Dragović T, Kiković S, et al. Fahr’s syndrome and idiopathic hypoparathyroidism – A case report. Vojnosanit Pregl 2017;74:184-8. DOI: https://doi.org/10.2298/VSP150916109M
3. Eaton LM, Camp JD, Lore JG. Symmetric cerebral calcification, particularly of basal ganglia, demonstrable roentgen no graphically; calcification of the finer cerebral blood vessels. Arch Neurol Psychiatr 1939;41:921-42. DOI: https://doi.org/10.1001/archneurpsyc.1939.02270170059003
4. Arruda ACG, Guerra ACDZ, Pessoa CH, et al. Hypoparathyroidism and Fahr’s syndrome: case series. J Bras Nefrol 2022;44:592-6. DOI: https://doi.org/10.1590/2175-8239-jbn-2020-0243
5. Braun GS, Witt M, Mayer V, Schmid H. Hypercalcemia caused by vitamin D3 analogs in psoriasis treatment. Int J Dermatol 2007;46:1315-7. DOI: https://doi.org/10.1111/j.1365-4632.2007.03347.x
6. Donzuso G, Mostile G, Nicoletti A, Zappia M. Basal ganglia calcifications (Fahr’s syndrome): related conditions and clinical features. Neurol Sci 2019;40:2251-63. DOI: https://doi.org/10.1007/s10072-019-03998-x
7. Benkirane S, Ziani J, Chhiti S, et al. Fahr Syndrome Secondary to Hypoparathyroidism with Dermatological Revelation. Dermatol Case Rep 2020;5:160.
8. Lazara N, El Azizi L, Salhi Pr H, Ouahabib H. Syndrome de Fahr révélé par un psoriasis. Ann Endocrinol (Paris) 2020;81:367-83. DOI: https://doi.org/10.1016/j.ando.2020.07.657
9. Shahriari M, Kerr PE, Slade K, Grant-Kels JE. Vitamin D and the skin. Clin Dermatol 2010;28:663-8. DOI: https://doi.org/10.1016/j.clindermatol.2010.03.030
10. Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007;6:428-35.
11. Noborio R, Kobayashi K, Shintani Y, Morita A. Comparison of the efficacy of calcipotriol and maxacalcitol in combination with narrow-band ultraviolet B therapy for the treatment of psoriasis vulgaris. Photodermatol Photoimmunol Photomed 2006;22:262-4. DOI: https://doi.org/10.1111/j.1600-0781.2006.00247.x
12. Plavina T, Hincapie M, Wakshull E, et al. Increased plasma concentrations of cytoskeletal and Ca2+-binding proteins and their peptides in psoriasis patients. Clin Chem 2008;54:1805-14. DOI: https://doi.org/10.1373/clinchem.2008.103770
13. Tissier M, Abou Nakad S, Vignon-Pennamen MD, et al. Severe hypocalcaemia-related pustular psoriasis in an 83-year-old woman with Fahr's syndrome: a case report. J Eur Acad Dermatol Venereol 2019;33:e42-3. DOI: https://doi.org/10.1111/jdv.15158
14. Tai XY, Batla A. Fahr’s disease: current perspectives. Orphan Drugs Res Rev 2015;5:43-9. DOI: https://doi.org/10.2147/ODRR.S63388

How to Cite



1.
Vargu M, Dedej S, Vargu P, Kurushi E, Nisi A, Vargu S. The role of calcium serum level in clinical manifestation and progress of psoriasis vulgaris in a patient with Fahr’s syndrome. Dermatol Reports [Internet]. 2025 Oct. 28 [cited 2026 Apr. 18];. Available from: https://journals.pagepress.net/dr/article/view/10614
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.